Farampator

From Self-sufficiency
Jump to: navigation, search
Farampator
180px
Systematic (IUPAC) name
2,1,3-benzoxadiazol-6-yl-piperidin-1-ylmethanone
Legal status
Legal status
  • Investigational New Medicine
Identifiers
CAS Number 211735-76-1
ATC code none
PubChem CID 4118151
Synonyms Farampator, CX-691
Chemical data
Formula C12H13N3O2
Molar mass 231.25052 g/mol[[Script error: No such module "String".]]
Script error: No such module "collapsible list".
Script error: No such module "TemplatePar".Expression error: Unexpected < operator.

Farampator (CX-691, ORG-24448) is an ampakine drug. It was developed by Cortex Pharmaceuticals, and licensed to Organon BioSciences for commercial development. Following the purchase of Organon by Schering-Plough in 2007, the development license to farampator has been transferred, and development is continuing.

Farampator has been investigated for its effect on AMPA receptors and researched for potential use in the treatment of schizophrenia and Alzheimer's Disease. It was found to improve short-term memory, but impaired episodic memory. It produced side effects (SEs) such as headache, somnolence and nausea. Subjects with SEs had significantly higher plasma levels of farampator than subjects without SEs. Additional analyses revealed that in the farampator condition the group without SEs showed a significantly superior memory performance relative to the group with SEs. [1]

References

  1. Wezenberg E, Verkes RJ, Ruigt GS, Hulstijn W, Sabbe BG. Acute effects of the ampakine farampator on memory and information processing in healthy elderly volunteers. Neuropsychopharmacology. 2007 Jun;32(6):1272-83. PMID 17119538